Subtype-dependent response of hepatitis B virus during the early phase of lamivudine treatment

Clinical Infectious Diseases

Volumn 34, Issue 9, 2002, Pages 1273-1277

  Zöllner, Bernhard ^a   Petersen, Jörg ^b   Schäfer, Peter ^a   Schräter, Matthias ^a   Laufs, Rainer ^a   Sterneck, Martina ^b   Feucht, Heinz Hubert ^a  

^a Medical Microbiology/Immunol Inst   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE;

ADOLESCENT; ADULT; AGED; ANTIVIRAL ACTIVITY; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; DRUG EFFECT; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MALE; PRIORITY JOURNAL; SCHOOL CHILD; STRAIN DIFFERENCE;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; CHILD; FEMALE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 0036570136     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/339959     Document Type: Article

References (20)

1. A one-year trial of lamivudine for chronic hepatitis B
2. Lamivudine as initial treatment for chronic hepatitis B in the United States
3. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: A randomised trial
4. Long-term therapy of chronic hepatitis B with lamivudine
5. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B
6. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapy
7. Incremental increases in HBeAg seroconversion and continued ALT normalization in Asian chronic HBV (CHB) patients treated with lamivudine for four years
8. 20-Fold increase in the risk of lamivudine resistance in hepatitis B virus subtype adw
9. High-throughput quantitative analysis of hepatitis B virus DNA in serum using the TaqMan fluorogenic detection method
10. Quantitative detection of Hepatitis B virus DNA in two international reference plasma preparations
11. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine
12. Comparison of the amino acid sequences of nine different serotypes of hepatitis B surface antigen and genomic classification of the corresponding hepatitis B virus strains
13. Some epidemiological and clinical aspects of hepatitis B antigen and its subtypes
14. Peginterferon alfa-2a in patients with chronic hepatitis C
15. Does hepatitis B virus (HBV) genotype influence the clinical outcome of HBV infection?
16. Genotype may correlate with liver carcinogenesis and tumor characteristics in cirrhotic patients infected with hepatitis B virus subtype adw
17. Correlation of hepatitis B virus load with loss of e antigen and emerging drug-resistant variants during lamivudine therapy
18. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B
19. Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: New perspectives for immune therapy
20. HIV treatment failure: Testing for HIV resistance in clinical practice